Recent Company News

• 06:44 PM ET Dec 01, 2025
  

  Clinuvel Pharmaceuticals provides NEURACTHEL update; targets EU filing mid-2026 (A$11.87, -0.01)

• 11:41 PM ET Nov 10, 2025
  

  Clinuvel Pharmaceuticals upgraded to speculative buy from hold at Morgans (A$11.12, +0.10)

• 05:59 PM ET Nov 02, 2025
  

  Clinuvel Pharmaceuticals anticipates delay to ADR upgrade due to ongoing U.S. Federal Government shutdown (A$11.50, 0.00)

• 08:41 PM ET Oct 07, 2025
  

  StreetAccount Summary - Trading higher/lower: Australia & New Zealand midday

• 10:03 PM ET Oct 16, 2025
  

  Clinuvel Pharmaceuticals receives first strike on remuneration report, as shareholders vote 63.0% against (A$11.70, -0.29)

• 08:35 AM ET Oct 16, 2025
  

  StreetAccount European Reads

• 09:50 PM ET Oct 15, 2025
  

  Clinuvel Pharmaceuticals notes Health Canada requests additional time for review of SCENESSE in EPP; review extended to 2026 (A$12.01, +0.20)

• 06:35 PM ET Sep 30, 2025
  

  Clinuvel Pharmaceuticals MD Philippe Wolgen has resumed his duties as CEO (A$11.80, 0.00)